As of 2026-03-30, the Relative Valuation of GT Biopharma Inc (GTBP) is (19.39) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.41 USD, the upside of GT Biopharma Inc based on Relative Valuation is -4841.2%.
The range of the Relative Valuation is (18.02) - (20.85) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.5x - 26.4x | 24.4x |
| Forward P/E multiples | 20.8x - 24.9x | 21.9x |
| Fair Price | (18.02) - (20.85) | (19.39) |
| Upside | -4507.3% - -5199.6% | -4841.2% |
| Date | P/E |
| 2026-03-23 | -0.56 |
| 2026-03-20 | -0.55 |
| 2026-03-19 | -0.51 |
| 2026-03-18 | -0.51 |
| 2026-03-17 | -0.52 |
| 2026-03-16 | -0.51 |
| 2026-03-13 | -0.49 |
| 2026-03-12 | -0.51 |
| 2026-03-11 | -0.53 |
| 2026-03-10 | -0.50 |
| 2026-03-09 | -0.50 |
| 2026-03-06 | -0.56 |
| 2026-03-05 | -0.56 |
| 2026-03-04 | -0.54 |
| 2026-03-03 | -0.56 |
| 2026-03-02 | -0.56 |
| 2026-02-27 | -0.57 |
| 2026-02-26 | -0.56 |
| 2026-02-25 | -0.54 |
| 2026-02-24 | -0.56 |
| 2026-02-23 | -0.54 |
| 2026-02-20 | -0.55 |
| 2026-02-19 | -0.54 |
| 2026-02-18 | -0.58 |
| 2026-02-17 | -0.55 |
| 2026-02-13 | -0.55 |
| 2026-02-12 | -0.56 |
| 2026-02-11 | -0.56 |
| 2026-02-10 | -0.62 |
| 2026-02-09 | -0.58 |
| 2026-02-06 | -0.64 |
| 2026-02-05 | -0.59 |
| 2026-02-04 | -0.63 |
| 2026-02-03 | -0.62 |
| 2026-02-02 | -0.61 |
| 2026-01-30 | -0.79 |
| 2026-01-29 | -0.81 |
| 2026-01-28 | -0.86 |
| 2026-01-27 | -0.88 |
| 2026-01-26 | -0.82 |
| 2026-01-23 | -0.85 |
| 2026-01-22 | -0.86 |
| 2026-01-21 | -0.85 |
| 2026-01-20 | -0.87 |
| 2026-01-16 | -0.89 |
| 2026-01-15 | -0.87 |
| 2026-01-14 | -0.79 |
| 2026-01-13 | -0.82 |
| 2026-01-12 | -0.87 |
| 2026-01-09 | -0.81 |